Tag: Truxima

Biosimilars generally cost 15% to 45% less than the originator biologic, making it highly likely that **is Truxima cheaper than rituximab?** Yes, it is, and this article explains why these cost savings are so crucial for patients and the healthcare system. Approved in 2018 as the first rituximab biosimilar, Truxima (rituximab-abbs) was launched with a significant discount compared to the brand-name Rituxan.

As of 2023, there are three FDA-approved biosimilars for Rituxan (rituximab) available in the United States, offering alternatives for patients and healthcare providers [1.5.3]. If you're asking, 'What is a substitute for RITUXAN?', it's important to understand these biosimilars and other therapeutic options.

The U.S. Food and Drug Administration (FDA) first approved Truxima (rituximab-abbs) in 2018 as a biosimilar to Rituxan [1.3.1]. This raises a critical question for patients and providers: Is Truxima as good as Rituxan? This article examines the evidence.

Over 90% of a patient's rituximab treatment cost can be attributed to the drug itself, highlighting the significant financial burden of this specialty medication. Given this, many people ask: **is there a generic for Rituxan?** The short answer is no, because Rituxan is a biologic drug, but several FDA-approved biosimilars now exist as more affordable, highly similar alternatives.

Truxima is a biosimilar drug to Rituxan, first approved by the FDA in November 2018 for the treatment of certain types of non-Hodgkin's lymphoma. This article explores what the drug **Truxima** is used for, including its various oncology and autoimmune indications, mechanism of action, and administration.